がん悪液質の世界市場レポート 2025年

がん悪液質市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.2％で、33億3,000万米ドルに成長します。予測期間の成長は、悪液質管理に対する意識の高まり、高齢者人口の拡大、新規治療アプローチの採用拡大、ヘルスケア支出の増加、政府の好意的な取り組みなどに起因すると考えられます。予測期間における主な動向には、研究開発努力の増加、治療選択肢の拡大、診断率の向上、新規治療法の採用、支持療法戦略の進歩などがあります。

がんの有病率の増加ががん悪液質市場の拡大を牽引すると予想されます。がんは、異常細胞の制御不能な増殖を特徴とする病態であり、腫瘍形成や正常な身体機能の崩壊をもたらします。がんの罹患率の増加は、ライフスタイルの変化、環境の影響、人口の高齢化、遺伝的素因、早期発見を可能にする診断技術の向上、より多くの人々が医療を受けるようになった社会意識の高まりなど、いくつかの要因に起因しています。医療技術の進歩や、がんとそれに関連する合併症に対する理解の深まりは、がん悪液質の診断や報告の頻度を高める一因となっています。ヘルスケアプロバイダーは悪液質の症状を特定することに習熟しつつあり、より早期の治療介入を可能にしています。例えば、2023年12月、オーストラリア統計局は、2022年にオーストラリア人口の約1.8％、45万6,200人ががんと診断されたと報告しました。さらに、米国の連邦機関である国立がん研究所は、2024年に米国で新たに200万1,140人のがん患者が診断され、61万1,720人が死亡すると予測しています。2022年には、世界全体で約2,000万人が新たにがんと診断され、970万人が死亡しました。2040年には、新たながん罹患者数は年間2,990万人に達し、がん関連死は1,530万人に上ると予想されています。このように、がんの有病率の増加ががん悪液質市場の成長を大きく促進しています。

がん悪液質市場の主なプレーヤーは、がん悪液質を管理し、患者の体重、筋肉量、全体的な生活の質を改善するための標的ソリューションを提供するために、モノクローナル抗体などの革新的な治療法の開発に注力しています。悪液質に対するモノクローナル抗体は、筋肉や体重の減少を引き起こす因子を標的とし、それを阻害することによって作用します。例えば、2024年9月、米国の製薬会社Pfizer Inc.は、がん悪液質患者を対象としたGDF-15を標的とするモノクローナル抗体Ponsegromabの第2相試験の良好な結果を報告しました。同試験では、筋肉量、食欲、身体活動性の改善とともに体重の有意な増加が認められ、400mg投与で最も顕著な結果が得られました。これらの有望な結果を受け、ファイザー社は、がん悪液質の治療薬としてのポンセグロマブの可能性をさらに追求するため、2025年に登録可能な試験を開始する予定です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界がん悪液質PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のがん悪液質市場：成長率分析
• 世界のがん悪液質市場の実績：規模と成長, 2019-2024
• 世界のがん悪液質市場の予測：規模と成長, 2024-2029, 2034F
• 世界がん悪液質総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがん悪液質市場セラピューティクス社、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロゲストーゲン
• コルチコステロイド
• 併用療法
• その他の治療薬
• 世界のがん悪液質市場作用機序別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 食欲増進剤
• 減量安定剤
• その他の作用機序
• 世界のがん悪液質市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院売店
• 小売薬局
• オンライン薬局
• 世界のがん悪液質市場プロゲストーゲンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メゲストロール酢酸塩
• メドロキシプロゲステロン酢酸塩
• ヒドロキシプロゲステロンカプロン酸
• 世界のがん悪液質市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• デキサメタゾン
• プレドニゾロン
• メチルプレドニゾロン
• 世界のがん悪液質市場併用療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロゲストーゲン+ コルチコステロイド
• プロゲストーゲン+ アナボリック剤
• コルチコステロイド+アナボリック剤
• 世界のがん悪液質市場その他の治療薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アナボリック剤
• 食欲増進剤
• 抗炎症薬
• 栄養補助食品

第7章 地域別・国別分析

• 世界のがん悪液質市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のがん悪液質市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん悪液質市場：競合情勢
• がん悪液質市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol Myers Squibb Company
• AstraZeneca plc
• Novartis International AG
• Fresenius SE & Co. KGaA
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company plc
• Kyowa Kirin Co. Ltd.
• Hikma Pharmaceuticals plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がん悪液質市場2029：新たな機会を提供する国
• がん悪液質市場2029：新たな機会を提供するセグメント
• がん悪液質市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. This multifactorial condition arises from a combination of factors, including inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient's quality of life, impair their ability to tolerate cancer treatments, and reduce overall survival.

The main therapeutics for cancer cachexia include progestogens, corticosteroids, combination therapies, and others. Progestogens, a type of medication often used in treating cancer cachexia, work by mimicking the effects of natural progesterone hormones in the body, potentially helping to increase appetite and muscle mass in patients. These treatments operate through various mechanisms, such as appetite stimulation and weight loss stabilization, and are distributed via hospital stores, retail pharmacies, and online pharmacies.

The cancer cachexia market research report is one of a series of new reports from The Business Research Company that provides cancer cachexia market statistics, including cancer cachexia industry global market size, regional shares, competitors with a cancer cachexia market share, detailed cancer cachexia market segments, market trends and opportunities, and any further data you may need to thrive in the cancer cachexia industry. This cancer cachexia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer cachexia market size has grown strongly in recent years. It will grow from $2.47 billion in 2024 to $2.62 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to an improved understanding of cancer biology, the prevalence of cancer, an increased aging population, a greater focus on patient-centered care, expanding treatment options, and growing awareness among healthcare providers.

The cancer cachexia market size is expected to see strong growth in the next few years. It will grow to $3.33 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising awareness about cachexia management, expanding geriatric population, growing adoption of novel therapeutic approaches, rising healthcare expenditure, and favorable government initiatives. Major trends in the forecast period include increasing research and development efforts, expanding therapeutic options, improved diagnosis rates, adoption of novel treatment modalities, and advancements in supportive care strategies.

The growing prevalence of cancer is expected to drive the expansion of the cancer cachexia market. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells, leading to tumor formation and disruption of normal bodily functions. The increasing incidence of cancer is attributed to several factors, including lifestyle changes, environmental influences, aging populations, genetic predisposition, improved diagnostic techniques allowing for earlier detection, and greater public awareness, leading more individuals to seek medical attention. Advances in medical technology and a deeper understanding of cancer and its associated complications are contributing to more frequent diagnoses and reporting of cancer cachexia. Healthcare providers are becoming more adept at identifying the symptoms of cachexia, enabling earlier treatment interventions. For example, in December 2023, the Australian Bureau of Statistics reported that approximately 1.8% of the Australian population, or 456,200 individuals, were diagnosed with cancer in 2022. Additionally, the National Cancer Institute, a US-based federal agency, projected that 2,001,140 new cancer cases would be diagnosed in the U.S. in 2024, with 611,720 expected deaths. In 2022, there were nearly 20 million new cases and 9.7 million cancer-related deaths globally. By 2040, the number of new cancer cases is expected to reach 29.9 million annually, with cancer-related deaths rising to 15.3 million. Thus, the increasing prevalence of cancer is significantly driving the growth of the cancer cachexia market.

Key players in the cancer cachexia market are focusing on developing innovative treatments, such as monoclonal antibodies, to provide targeted solutions for managing cancer cachexia and improving patients' body weight, muscle mass, and overall quality of life. Monoclonal antibodies for cachexia work by targeting and inhibiting the factors responsible for muscle and weight loss. For example, in September 2024, Pfizer Inc., a US-based pharmaceutical company, reported the positive results from its Phase 2 trial of Ponsegromab, a monoclonal antibody aimed at targeting GDF-15 in cancer cachexia patients. The study showed a significant increase in body weight, along with improvements in muscle mass, appetite, and physical activity, with the 400 mg dose yielding the most notable results. Following these encouraging outcomes, Pfizer plans to launch registration-enabling studies in 2025 to further explore Ponsegromab's potential as a treatment for cancer cachexia.

In January 2023, LG Chem Ltd., a South Korean chemical company, acquired AVEO Oncology for an undisclosed amount. This acquisition aims to diversify LG Chem's product portfolio and enhance its capabilities in drug development, commercialization, and acquisitions, thereby accelerating its progress toward delivering cutting-edge cancer treatments. AVEO Oncology, a US-based biopharmaceutical company, provides a potential treatment for cancer cachexia.

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

North America was the largest region in the cancer cachexia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer cachexia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer cachexia market consists of revenues earned by entities by providing services such as nutritional counseling, physical therapy, and exercise training. The market value includes the value of related goods sold by the service provider or included within the service offering. The cancer cachexia market also includes sales of anabolic steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and oral nutritional supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Cachexia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer cachexia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer cachexia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer cachexia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutics: Progestogens; Corticosteroids; Combination Therapies; Other Therapeutics
• 2) By Mechanism Of Action: Appetite Stimulators; Weight Loss Stabilizers; Other Mechanisms Of Actions
• 3) By Distribution Channel: Hospital Stores; Retail Pharmacy Stores; Online Pharmacies
• Subsegments:
• 1) By Progestogens: Megestrol Acetate; Medroxyprogesterone Acetate; Hydroxyprogesterone Caproate
• 2) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone
• 3) By Combination Therapies: Progestogens + Corticosteroids; Progestogens + Anabolic Agents; Corticosteroids + Anabolic Agents
• 4) By Other Therapeutics: Anabolic Agents; Appetite Stimulants; Anti-inflammatory Drugs; Nutritional Supplements
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Cachexia Market Characteristics

3. Cancer Cachexia Market Trends And Strategies

4. Cancer Cachexia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cancer Cachexia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cancer Cachexia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cancer Cachexia Market Growth Rate Analysis
• 5.4. Global Cancer Cachexia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cancer Cachexia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cancer Cachexia Total Addressable Market (TAM)

6. Cancer Cachexia Market Segmentation

• 6.1. Global Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Progestogens
• Corticosteroids
• Combination Therapies
• Other Therapeutics
• 6.2. Global Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Appetite Stimulators
• Weight Loss Stabilizers
• Other Mechanisms Of Actions
• 6.3. Global Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Stores
• Retail Pharmacy Stores
• Online Pharmacies
• 6.4. Global Cancer Cachexia Market, Sub-Segmentation Of Progestogens, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Megestrol Acetate
• Medroxyprogesterone Acetate
• Hydroxyprogesterone Caproate
• 6.5. Global Cancer Cachexia Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dexamethasone
• Prednisolone
• Methylprednisolone
• 6.6. Global Cancer Cachexia Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Progestogens + Corticosteroids
• Progestogens + Anabolic Agents
• Corticosteroids + Anabolic Agents
• 6.7. Global Cancer Cachexia Market, Sub-Segmentation Of Other Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anabolic Agents
• Appetite Stimulants
• Anti-inflammatory Drugs
• Nutritional Supplements

7. Cancer Cachexia Market Regional And Country Analysis

• 7.1. Global Cancer Cachexia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cancer Cachexia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Cachexia Market

• 8.1. Asia-Pacific Cancer Cachexia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Cachexia Market

• 9.1. China Cancer Cachexia Market Overview
• 9.2. China Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Cachexia Market

• 10.1. India Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Cachexia Market

• 11.1. Japan Cancer Cachexia Market Overview
• 11.2. Japan Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Cachexia Market

• 12.1. Australia Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Cachexia Market

• 13.1. Indonesia Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Cachexia Market

• 14.1. South Korea Cancer Cachexia Market Overview
• 14.2. South Korea Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Cachexia Market

• 15.1. Western Europe Cancer Cachexia Market Overview
• 15.2. Western Europe Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Cachexia Market

• 16.1. UK Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Cachexia Market

• 17.1. Germany Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Cachexia Market

• 18.1. France Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Cachexia Market

• 19.1. Italy Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Cachexia Market

• 20.1. Spain Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Cachexia Market

• 21.1. Eastern Europe Cancer Cachexia Market Overview
• 21.2. Eastern Europe Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Cachexia Market

• 22.1. Russia Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Cachexia Market

• 23.1. North America Cancer Cachexia Market Overview
• 23.2. North America Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Cachexia Market

• 24.1. USA Cancer Cachexia Market Overview
• 24.2. USA Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Cachexia Market

• 25.1. Canada Cancer Cachexia Market Overview
• 25.2. Canada Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Cachexia Market

• 26.1. South America Cancer Cachexia Market Overview
• 26.2. South America Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Cachexia Market

• 27.1. Brazil Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Cachexia Market

• 28.1. Middle East Cancer Cachexia Market Overview
• 28.2. Middle East Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Cachexia Market

• 29.1. Africa Cancer Cachexia Market Overview
• 29.2. Africa Cancer Cachexia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cancer Cachexia Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cancer Cachexia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Cachexia Market Competitive Landscape And Company Profiles

• 30.1. Cancer Cachexia Market Competitive Landscape
• 30.2. Cancer Cachexia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Cachexia Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Novartis International AG
• 31.4. Fresenius SE & Co. KGaA
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company
• 31.7. Eli Lilly and Company
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Astellas Pharma Inc.
• 31.11. Daiichi Sankyo Company Limited
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Perrigo Company plc
• 31.14. Kyowa Kirin Co. Ltd.
• 31.15. Hikma Pharmaceuticals plc

32. Global Cancer Cachexia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Cachexia Market

34. Recent Developments In The Cancer Cachexia Market

35. Cancer Cachexia Market High Potential Countries, Segments and Strategies

• 35.1 Cancer Cachexia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cancer Cachexia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cancer Cachexia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer